Banff 2011 Meeting report: new concepts in antibody-mediated rejection
M Mengel, B Sis, M Haas, R B Colvin, P F Halloran, L C Racusen, K Solez, L Cendales, A J Demetris, C B Drachenberg, C F Farver, E R Rodriguez, W D Wallace, D Glotz, Banff meeting report writing committee, M Mengel, B Sis, M Haas, R B Colvin, P F Halloran, L C Racusen, K Solez, L Cendales, A J Demetris, C B Drachenberg, C F Farver, E R Rodriguez, W D Wallace, D Glotz, Banff meeting report writing committee
Abstract
The 11th Banff meeting was held in Paris, France, from June 5 to 10, 2011, with a focus on refining diagnostic criteria for antibody-mediated rejection (ABMR). The major outcome was the acknowledgment of C4d-negative ABMR in kidney transplants. Diagnostic criteria for ABMR have also been revisited in other types of transplants. It was recognized that ABMR is associated with heterogeneous phenotypes even within the same type of transplant. This highlights the necessity of further refining the respective diagnostic criteria, and is of particular significance for the design of randomized clinical trials. A reliable phenotyping will allow for definition of robust end-points. To address this unmet need and to allow for an evidence-based refinement of the Banff classification, Banff Working Groups presented multicenter data regarding the reproducibility of features relevant to the diagnosis of ABMR. However, the consensus was that more data are necessary and further Banff Working Group activities were initiated. A new Banff working group was created to define diagnostic criteria for ABMR in kidneys independent of C4d. Results are expected to be presented at the 12th Banff meeting to be held in 2013 in Brazil. No change to the Banff classification occurred in 2011.
Conflict of interest statement
Conflict of interest
Michael Mengel and Banu Sis received a research grant from Astellas Canada in support for the Banff Working Group activities. Michael Mengel is a consultant to Novartis Canada. Denis Glotz received honoraria/speaker’s fees from Roche, Novartis, Pfizer, Genzyme, Alexion, ORS, CSL Behring. None of the other authors has any conflicts of interest to disclose as described by the American Journal of Transplantation.
© copyright 2012 The American Society of Transplantation and the American Society of Transplant Surgeons.
Source: PubMed